يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"Inflammatory Bowel Diseases/chemically induced/drug therapy"', وقت الاستعلام: 0.42s تنقيح النتائج
  1. 1
    Academic Journal
    How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study.

    المؤلفون: Cottron, C, Treton, X, Altwegg, R, Reenaers, Catherine, Amiot, A, Fumery, M, Vuitton, L, Peyrin-Biroulet, L, Bouguen, G, Dewit, O, Nancey, S, Caillo, L, Roblin, X, Beylot-Barry, M, Rivière, P, Laharie, D

    المصدر: Journal of Crohn's and Colitis, 16 (8), 1202-1210 (2022-08-30)

    مصطلحات موضوعية: Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha, B72HH48FLU (Infliximab), FYS6T7F842 (Adalimumab), Adalimumab/adverse effects, Cohort Studies, Crohn Disease/chemically induced/drug therapy, Female, Humans, Inflammatory Bowel Diseases/chemically induced/drug therapy, Infliximab/adverse effects, Necrosis/chemically induced/drug therapy, Recurrence, Retrospective Studies, Skin Diseases/drug therapy, Tumor Necrosis Factor Inhibitors/adverse effects, Inflammatory bowel disease, anti-TNF, skin lesions, Human health sciences, Gastroenterology & hepatology, Sciences de la santé humaine, Gastroentérologie & hépatologie

    Relation: https://doi.org/10.1093/ecco-jcc/jjac035; 10.1093/ecco-jcc/jjac035; urn:issn:1873-9946; urn:issn:1876-4479

    URL الوصول: https://orbi.uliege.be/handle/2268/311916

    View record in ORBi

    أضف إلى المفضلة
  2. 2
    Academic Journal
    Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.

    المؤلفون: Peyrin-Biroulet, Laurent, Arkkila, Perttu, Armuzzi, Alessandro, Danese, Silvio, Guardiola, Jordi, Jahnsen, Jørgen, Lees, Charles, Louis, Edouard, Lukáš, Milan, Reinisch, Walter, Roblin, Xavier, Jang, Minyoung, Byun, Han Geul, Kim, Dong-Hyeon, Lee, Sung Jeong, Atreya, Raja

    المصدر: BMC Gastroenterology, 22 (1), 291 (2022-06-08)

    مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, 9RV78Q2002 (vedolizumab), B72HH48FLU (Infliximab), Adult, Colitis, Ulcerative/chemically induced/drug therapy, Crohn Disease/chemically induced/drug therapy, Gastrointestinal Agents/adverse effects, Humans, Inflammatory Bowel Diseases/chemically induced/drug therapy, Infliximab/adverse effects, Antibodies, Biological therapy, Crohn’s disease, IBD, Monoclonal, Tumor Necrosis Factor-alpha, Ulcerative colitis, Human health sciences, Gastroenterology & hepatology, Sciences de la santé humaine, Gastroentérologie & hépatologie

    Relation: https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02347-1; urn:issn:1471-230X

    URL الوصول: https://orbi.uliege.be/handle/2268/300180

    View record in ORBi

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء